<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04126538</url>
  </required_header>
  <id_info>
    <org_study_id>GNI-F647-1703</org_study_id>
    <nct_id>NCT04126538</nct_id>
  </id_info>
  <brief_title>Pirfenidone Capsule in Patients With Chronic Kidney Disease G2 and G3a Study on Safety and Pharmacokinetics</brief_title>
  <official_title>Pirfenidone Capsule in Patients With Chronic Kidney Disease G2 and G3a Study on Safety and Pharmacokinetics of Single Dose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Continent Pharmaceutical Co, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Continent Pharmaceutical Co, Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and pharmacokinetic characteristics of pirfenidone capsules in chronic
      kidney disease G2 and G3a patients, and to provide a basis for the phase II clinical trial
      program
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 27, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma drug concentrations of pirfenidone</measure>
    <time_frame>up to 24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine concentration of pirfenidone</measure>
    <time_frame>up to 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>up to 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>Patient group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with chronic kidney disease take pirfenidone capsule 400mg once orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects take pirfenidone capsule 400mg once orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pirfenidone capsule</intervention_name>
    <description>In the patient group, pirfenidone capsule was taken orally once for 400mg</description>
    <arm_group_label>Patient group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pirfenidone capsule</intervention_name>
    <description>Healthy subjects took pirfenidone capsule 400mg once orally</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. patients with chronic kidney disease, both male and female（Patient group）;

          2. 18-70 years old, including 18 years old and 70 years old（Patient group）;

          3. weight: male ≥50kg, female ≥45kg, 18≤BMI≤26 (BMI= weight (kg)/height 2 (m2))（Patient
             group）;

          4. the stage of chronic kidney disease was G2 or G3a, indicating mild or moderate
             decrease in GFR, i.e., glomerular filtration rate was 45≤eGFR(ml/min/1.73m2) ≤89
             (calculated according to ckd-epi formula)（Patient group）;

          5. from 24h before the start of the study to the end of the study, subjects who agree to
             abstain from tobacco, alcohol, fruit juice, caffeine and tea（Patient group）;

          6. I have had a detailed understanding of the nature, significance, possible benefits,
             possible inconvenience and potential risks of the trial before the study, and I have
             volunteered to participate in the clinical trial. I am able to communicate well with
             the investigator, comply with the requirements of the whole study, and have the
             ability to understand and sign the written informed consent.（Patient group）;

          7. gender: Chinese healthy subjects, male and female（Control group）;

          8. 18-70 years old, including 18 years old and 70 years old（Control group）;

          9. weight: male ≥50kg, female ≥45kg, 18≤BMI≤26 (BMI= weight (kg)/height 2 (m2))（Control
             group）;

         10. from 24h before the start of the study to the end of the study, subjects who agree to
             abstain from tobacco, alcohol, fruit juice, caffeine and tea（Control group）;

         11. those who have detailed understanding of the nature, significance, potential benefits,
             possible inconveniences and potential risks of the trial before the study, who have
             volunteered to participate in the clinical trial, who can communicate well with the
             investigator, comply with the requirements of the whole study, and who are able to
             understand and sign a written informed consent（Control group）;

        Exclusion Criteria:

          1. （Physician visits） have participated in any other clinical trials within the first
             three months of the trial（Patient group）;

          2. (preliminary) of any process may affect test security, or drug in the body of the
             disease, not including chronic kidney disease (CKD), including but not limited to:
             heart, liver, gastrointestinal tract, immune system and respiratory system always or
             the existing system diseases (especially for any impact on drug absorption of
             gastrointestinal diseases (such as irritable bowel syndrome symptoms, bowel disease or
             inflammatory bowel disease), active pathological bleeding (such as peptic ulcer),
             urticaria, eczema, dermatitis, epilepsy, allergic rhinitis, asthma, etc.)（Patient
             group）;

          3. (consultation) allergy: if there are two or more drugs, food allergy history
             (including experimental drugs), lactose intolerance（Patient group）;

          4. (consultation) any drugs that inhibit or induce drug metabolism in the liver (common
             liver enzyme inducers: barbiturates, carbamazepine, aminoximate, griseofulvin,
             aminopropyl, phenytoin, gromitol, rifampin, dexamethasone; Common liver enzyme
             inhibitors: chlorpromazine, cimetidine, ciprofloxacin, metronidazole, chloramphenicol,
             isoniazid, sulfonamide)（Patient group）;

          5. (consultation) failure to follow a uniform diet (such as intolerance to standard
             meals, etc.) or difficulty swallowing（Patient group）;

          6. (consultation) unable to tolerate venipuncture and/or having a history of blood or
             acupuncture（Patient group）;

          7. (consultation) patients who have been drinking excessive amounts of tea, coffee or
             caffeinated drinks (more than 8 cups a day, 1 cup =250mL) for a long time; Or taking
             any food or beverage containing caffeine (such as coffee, strong tea, chocolate, etc.)
             within 24 hours before the first administration of the drug（Patient group）;

          8. (consultation) previous binge drinking (i.e., male drinking more than 28 units per
             week and female drinking more than 21 units per week (1 unit contains 14g alcohol,
             such as 360 mL beer or 45 mL spirits with 40% alcohol or 150 mL wine); Or who had
             regularly consumed alcohol (more than 14 units per week) during the 6 months prior to
             the trial; Or who had taken any alcoholic product within 24 hours of initial
             administration（Patient group）;

          9. (consultation) those who had donated blood or suffered massive bleeding (greater than
             450 mL) within 3 months before the first administration of the study, or who planned
             to donate blood or blood components during the study period or within 3 months after
             the end of the study（Patient group）;

         10. (consultation) acute disease during the screening phase before study or before study
             medication（Patient group）;

         11. (consultation) patients who had taken food or drinks containing enzymes that can
             induce or inhibit liver metabolism (e.g., grapefruit, mango, pitaya, grape juice,
             orange juice, etc., rich in flavonoids or citrus glycosides) within 24 hours before
             the first administration were studied（Patient group）;

         12. pregnant or lactating women, and subjects (or their partners) who have a pregnancy
             plan during the trial and within 3 months after the end of the study and who do not
             agree to use non-drug contraception during the trial（Patient group）;

         13. (consultation) those who have had surgery within three months before the screening
             period, or who are planning to have surgery during the study period, and those who
             have had surgery that will affect drug absorption, distribution, metabolism and
             excretion（Patient group）;

         14. (consultation) previous history of drug abuse or drug abuse（Patient group）;

         15. (consultation) persons who have smoked more than 5 cigarettes per day in the 14 days
             before screening, or who cannot stop using any tobacco products during the
             trial（Patient group）;

         16. screening for smoking or using any tobacco products up to admission（Patient group）;

         17. screening phase physical examination, vital signs measurement, electrocardiogram
             examination, laboratory examination (hematuria routine, blood coagulation function,
             blood pregnancy (women of childbearing age only)) and investigator determination of
             clinically significant abnormalities (excluding abnormalities caused by chronic kidney
             disease). Abnormal liver function examination (ALT, AST, ALP, gamma GT, TP, Alb, A/G,
             t-bil, d-bil) suggested liver disease or liver injury. Renal function test SCr &gt; 400
             mol/L; Abnormal blood electrolyte examination (K+, Na+, Cl-, Ca2+) suggested high
             potassium or acidosis.（Patient group）

         18. nicotine positive test（Patient group）;

         19. alcohol breath test with test results greater than 0.0mg/100ml（Patient group）;

         20. positive urine drug screening（Patient group）;

         21. hepatitis b surface antigen positive, or hepatitis c antibody positive, or syphilis
             spirochete antibody positive, or HIV antibody positive（Patient group）;

         22. the investigator considers that there are any circumstances that may affect the
             subject's informed consent or adherence to the study protocol, or participation in the
             study may affect the study results or their own safety.（Patient group）;

         23. （Physician visits）those who participated in any other clinical trials three months
             prior to the trial（Control group）;

         24. (preliminary) of any process may affect test security, or drug in the body of the
             disease, including but not limited to: heart, liver, kidney, endocrine, the digestive
             tract, immune system and respiratory system always or the existing system diseases
             (especially cardiovascular diseases including cardiovascular disease risk, any impact
             on drug absorption of gastrointestinal diseases (such as irritable bowel syndrome
             symptoms, bowel disease or inflammatory bowel disease), active pathological bleeding
             (such as peptic ulcer), urticaria, eczema, dermatitis, epilepsy, allergic rhinitis,
             asthma, etc.)（Control group）;

         25. (consultation) allergy: if there are two or more drugs, food allergy history
             (including experimental drugs), lactose intolerance（Control group）;

         26. (consultation) any drugs that inhibit or induce drug metabolism in the liver (common
             liver enzyme inducers: barbiturates, carbamazepine, aminoximate, griseofulvin,
             aminopropyl, phenytoin, gromitol, rifampin, dexamethasone; Common liver enzyme
             inhibitors: chlorpromazine, cimetidine, ciprofloxacin, metronidazole, chloramphenicol,
             isoniazid, sulfonamide); Or have used any medicines (including Chinese herbal
             medicines) or health supplements within 14 days prior to initial
             administration（Control group）;

         27. (consultation) failure to follow a uniform diet (such as intolerance to standard
             meals, etc.) or difficulty swallowing（Control group）;

         28. (consultation) unable to tolerate venipuncture and/or having a history of blood or
             acupuncture（Control group）;

         29. (consultation) patients who have been drinking excessive amounts of tea, coffee or
             caffeinated drinks (more than 8 cups a day, 1 cup =250mL) for a long time; Or taking
             any food or beverage containing caffeine (such as coffee, strong tea, chocolate, etc.)
             within 24 hours before the first administration of the drug（Control group）;

         30. (consultation) previous binge drinking (i.e., male drinking more than 28 units per
             week and female drinking more than 21 units per week (1 unit contains 14g alcohol,
             such as 360 mL beer or 45 mL spirits with 40% alcohol or 150 mL wine); Or who had
             regularly consumed alcohol (more than 14 units per week) during the 6 months prior to
             the trial; Or who had taken any alcoholic product within 24 hours of initial
             administration（Control group）;

         31. (consultation) those who had donated blood or suffered massive bleeding (greater than
             450 mL) within 3 months before the first administration of the study, or who planned
             to donate blood or blood components during the study period or within 3 months after
             the end of the study（Control group）;

         32. (consultation) acute disease during the screening phase before study or before study
             medication（Control group）;

         33. (consultation) patients who had taken food or drinks containing enzymes that can
             induce or inhibit liver metabolism (e.g., grapefruit, mango, pitaya, grape juice,
             orange juice, etc., rich in flavonoids or citrus glycosides) within 24 hours before
             the first administration were studied（Control group）;

         34. pregnant or lactating women, and subjects (or their partners) who have a pregnancy
             plan during the trial and within 3 months after the end of the study and who do not
             agree to use non-drug contraception during the trial（Control group）;

         35. (consultation) those who have had surgery within three months before the screening
             period, or who are planning to have surgery during the study period, and those who
             have had surgery that will affect drug absorption, distribution, metabolism and
             excretion（Control group）;

         36. (consultation) previous history of drug abuse or drug abuse（Control group）;

         37. (consultation) persons who have smoked more than 5 cigarettes per day in the 14 days
             before screening, or who cannot stop using any tobacco products during the
             trial（Control group）;

         38. screening for smoking or using any tobacco products up to admission（Control group）;

         39. screening phase physical examination, vital signs measurement, electrocardiogram
             examination, b-mode ultrasound examination, laboratory examination [blood routine,
             urine routine, blood biochemistry, blood coagulation function, blood pregnancy (women
             of childbearing age only)], and the investigator judged that abnormalities were
             clinically significant（Control group）;

         40. those with positive nicotine test results（Control group）;

         41. alcohol breath test with test results greater than 0.0mg/100ml（Control group）;

         42. positive urine drug screening（Control group）;

         43. hepatitis b surface antigen positive, or hepatitis c antibody positive, or syphilis
             spirochete antibody positive, or HIV antibody positive（Control group）;

         44. the investigator considers that there are any circumstances that may affect the
             subject's informed consent or adherence to the study protocol, or participation in the
             study may affect the study results or their own safety.（Control group）.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shaojun Shaojun, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wuhan Union Hospital, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shaojun Shi, Doctor</last_name>
    <phone>027-85726085</phone>
    <email>sjshicn@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wuhan Union Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaojun Shi, Doctor</last_name>
      <phone>027-85726085</phone>
      <email>sjshicn@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>October 10, 2019</study_first_submitted>
  <study_first_submitted_qc>October 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2019</study_first_posted>
  <last_update_submitted>October 11, 2019</last_update_submitted>
  <last_update_submitted_qc>October 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pirfenidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

